Percentage of tumor and tumor length in prostate biopsy specimens: A study of American Veterans

American Journal of Clinical Pathology

Volumn 130, Issue 6, 2008, Pages 940-943

  Vollmer, Robin T ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

Author keywords

Age; Grade; Needle biopsies; Prostate cancer; Serum PSA; Survival; Tumor length; Tumor percentage; Tumor size

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; FOLLOW UP; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NEEDLE BIOPSY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; TUMOR VOLUME; VETERAN;

BIOPSY; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; NEOPLASM STAGING; PROSTATE; PROSTATIC NEOPLASMS; UNITED STATES; VETERANS;

EID: 58049208375     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/AJCP3VUXBYTEY3PU     Document Type: Article

References (9)

1. Gleason DF. Histologic grading and clinical staging of prostatic carcinoma. In: Tannenbaum M, ed. Urologic Pathology: The Prostate. Philadelphia, PA: Lea & Febiger; 1977:171-198.
2. Vollmer RT. Tumor length in prostate cancer. Am J Clin Pathol. 2008;130:77-82.
3. Cookson MS, Aus G, Burnett AL, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: The American Urological Association prostate guidelines for localized prostate cancer update panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol. 2007;177:540-545.
4. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591-1597.
5. Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294:433-439.
6. Thames H, Kuban D, Levy L, et al. Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiation Oncology Biol Phys. 2003;57:929-943.
7. Vollmer RT, Montana GS. The dynamics of prostate-specific antigen after definitive radiation therapy for prostate cancer. Clin Cancer Res. 1999;5:4119-4125.
8. Epstein JL, Allsbrook WC Jr, Amin MB, et al. The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostate cancer. Am J Surg Pathol. 2005;9:1228-1242.
9. Hosmer DW, Lemeshow S. Applied Survival Analysis: Regression Modeling of Time to Event Data. New York, NY: Wiley; 1999.